NXTC (NextCure) Beginning Cash Position : $27.73 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is NextCure Beginning Cash Position?

NextCure's Beginning Cash Position for the quarter that ended in Mar. 2025 was $27.73 Mil.

NextCure's quarterly Beginning Cash Position increased from Sep. 2024 ($20.85 Mil) to Dec. 2024 ($27.70 Mil) and increased from Dec. 2024 ($27.70 Mil) to Mar. 2025 ($27.73 Mil).

NextCure's annual Beginning Cash Position increased from Dec. 2022 ($12.34 Mil) to Dec. 2023 ($26.63 Mil) but then declined from Dec. 2023 ($26.63 Mil) to Dec. 2024 ($13.08 Mil).

NextCure Beginning Cash Position Historical Data

The historical data trend for NextCure's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure Beginning Cash Position Chart

NextCure Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

Get a 7-Day Free Trial

39.13

36.28

12.34

26.63

13.08

NextCure Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Beginning Cash Position	Get a 7-Day Free Trial															13.08	18.36	20.85	27.70	27.73

NextCure Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

NextCure Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of NextCure's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCure Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (NAS:NXTC) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

2US:Germany

Address

9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705

Website

https://www.nextcure.com

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Executives

Anne Elizabeth Borgman	director	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Ellen Feigal	director	C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Kevin G. Shaw	officer: Sr VP, Legal Affairs	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sourav Kundu	officer: Sr VP, Dev. & Mfg.	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Han Myint	officer: Chief Medical Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Timothy Mayer	officer: Chief Operating Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sol Langermann	officer: Chief Scientific Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Steven P. Cobourn	officer: Chief Financial Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Linda Liu	officer: SVP, Research	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Michael Richman	director, officer: President & CEO	2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
John G Houston	director	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Anand Mehra	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Michael Powell	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
James Healy	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025